Cover Image
市場調查報告書

Aestus Therapeutics, Inc.的產品平台分析

Aestus Therapeutics, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 277766
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
Aestus Therapeutics, Inc.的產品平台分析 Aestus Therapeutics, Inc. - Product Pipeline Review - 2015
出版日期: 2015年03月26日 內容資訊: 英文 29 Pages
簡介

Aestus Therapeutics, Inc.是總公司設立於美國的製藥企業,專門開發、提供中樞神經系統疾病和神經病變痛、思覺失調症、葛雷克氏症(Lou Gehrig's disease)ALS、癲癇、等治療藥。

本報告提供Aestus Therapeutics, Inc. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Aestus Therapeutics, Inc. 的基本資料

  • Aestus Therapeutics, Inc. 概要
  • 主要資訊
  • 企業資料

Aestus Therapeutics, Inc. :R&D概要

  • 主要的治療範圍

Aestus Therapeutics, Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Aestus Therapeutics, Inc. :開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Aestus Therapeutics, Inc. :藥物簡介

  • Atx08-001
  • Atx09-002
  • ATx11-004
  • Drug for Epilepsy
  • Small Molecule for Amyotrophic Lateral Sclerosis

Aestus Therapeutics, Inc. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Aestus Therapeutics, Inc. :最新的開發平台資訊

Aestus Therapeutics, Inc. :開發暫停中的計劃

Aestus Therapeutics, Inc. :開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • Atx08-001
    • Atx09-002

Aestus Therapeutics, Inc. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06881CDB

Summary

Global Markets Direct's, 'Aestus Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Aestus Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Aestus Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Aestus Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Aestus Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Aestus Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Aestus Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Aestus Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Aestus Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Aestus Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Aestus Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Aestus Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Aestus Therapeutics, Inc. Snapshot
    • Aestus Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Aestus Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Aestus Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Aestus Therapeutics, Inc. - Pipeline Products Glance
    • Aestus Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Aestus Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Aestus Therapeutics, Inc. - Drug Profiles
    • Atx08-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Atx09-002
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATx11-004
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug for Epilepsy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Amyotrophic Lateral Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Aestus Therapeutics, Inc. - Pipeline Analysis
    • Aestus Therapeutics, Inc. - Pipeline Products by Target
    • Aestus Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Aestus Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Aestus Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Aestus Therapeutics, Inc. - Recent Pipeline Updates
  • Aestus Therapeutics, Inc. - Dormant Projects
  • Aestus Therapeutics, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • Atx08-001
      • Atx09-002
  • Aestus Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Aestus Therapeutics, Inc., Key Information
  • Aestus Therapeutics, Inc., Key Facts
  • Aestus Therapeutics, Inc. - Pipeline by Indication, 2015
  • Aestus Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Aestus Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Aestus Therapeutics, Inc. - Phase II, 2015
  • Aestus Therapeutics, Inc. - Phase I, 2015
  • Aestus Therapeutics, Inc. - Preclinical, 2015
  • Aestus Therapeutics, Inc. - Pipeline by Target, 2015
  • Aestus Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • Aestus Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Aestus Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Aestus Therapeutics, Inc. - Recent Pipeline Updates, 2015
  • Aestus Therapeutics, Inc. - Dormant Developmental Projects,2015
  • Aestus Therapeutics, Inc. - Discontinued Pipeline Products, 2015

List of Figures

  • Aestus Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Aestus Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Aestus Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Aestus Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • Aestus Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Aestus Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Aestus Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top